

FEE TRANSMITTAL

Patent fees are subject to annual revision.

APR 18 2002

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/031,691 |
| Filing Date | January 22, 2002 |
| First Named Inventor | Uebele, et al. |
| Examiner Name | |
| Group Art Unit | |
| Attorney Docket Number | 20499P |

TOTAL AMOUNT OF PAYMENT

\$130

METHOD OF PAYMENT (Check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number

Deposit Account Name

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

2. ☐ Payment Enclosed:

☐ Check ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

| Large Fee Code | Entity Fee (\$) | Fee Description | Fee Paid |
|----------------|-----------------|------------------------|----------------------------------|
| 101 | 740 | Utility filing fee | <input type="text"/> |
| 106 | 330 | Design filing fee | <input type="text"/> |
| 108 | 740 | Reissue filing fee | <input type="text"/> |
| 114 | 160 | Provisional filing fee | <input type="text"/> |
| SUBTOTAL(1) | | | <input type="text" value="\$0"/> |

2. EXTRA CLAIM FEES

| | Extra | Fee from below | Fee Paid |
|---|-------------------------------------|----------------|--------------------------------|
| Total Claims <input type="text" value="20"/> | ** = <input type="text" value="0"/> | x \$18 = | <input type="text" value="0"/> |
| Independent Claims <input type="text" value="3"/> | ** = <input type="text" value="0"/> | x \$84 = | <input type="text" value="0"/> |
| Multiple Dependent Claims | | \$280 = | <input type="text"/> |

**or number previously paid, if greater; For Reissues, see below


| Large Fee Code | Entity Fee (\$) | Fee Description |
|----------------|-----------------|---|
| 103 | 18 | Claims in excess of 20 |
| 102 | 84 | Independent claims in excess of 3 |
| 104 | 280 | Multiple dependent claim, if not paid |
| 109 | 84 | **Reissue independent claims over original patent |
| 110 | 18 | **Reissue claims in excess of 20 and over original patent |
| SUBTOTAL(2) | | <input type="text" value="\$0"/> |

3. ADDITIONAL FEES


| Large Fee Code | Entity Fee (\$) | Fee Description | Fee Paid |
|---------------------------|-----------------|--|------------------------------------|
| 105 | 130 | Surcharge - late filing fee or oath | <input type="text" value="130"/> |
| 147 | 2,520 | For filing a request for reexamination | <input type="text"/> |
| 115 | 110 | Extension for reply within first month | <input type="text"/> |
| 116 | 400 | Extension for reply within second month | <input type="text"/> |
| 117 | 920 | Extension for reply within third month | <input type="text"/> |
| 118 | 1,440 | Extension for reply within fourth month | <input type="text"/> |
| 128 | 1,960 | Extension for reply within fifth month | <input type="text"/> |
| 119 | 320 | Notice of Appeal | <input type="text"/> |
| 120 | 320 | Filing a brief in support of an appeal | <input type="text"/> |
| 121 | 280 | Request for oral hearing | <input type="text"/> |
| 140 | 110 | Petition to revive - unavoidable | <input type="text"/> |
| 141 | 1,280 | Petition to revive - unintentional | <input type="text"/> |
| 142 | 1,280 | Utility issue fee (or reissue) | <input type="text"/> |
| 143 | 460 | Design issue fee | <input type="text"/> |
| 122 | 130 | Petitions to the Commissioner | <input type="text"/> |
| 123 | 50 | Petitions related to provisional applications | <input type="text"/> |
| 126 | 180 | Submission of Information Disclosure Statement | <input type="text"/> |
| 581 | 40 | Recording each patent assignment per property (times number of properties) | <input type="text"/> |
| 146 | 740 | Filing a submission after final rejection (37 CFR 1.129(a)) | <input type="text"/> |
| 149 | 740 | For each additional invention to be examined (37 CFR 1.129(b)) | <input type="text"/> |
| 179 | 740 | Request for Continued Examination (RCE) | <input type="text"/> |
| Other fee (specify) _____ | | | <input type="text"/> |
| Other fee (specify) _____ | | | <input type="text"/> |
| SUBTOTAL(3) | | | <input type="text" value="\$130"/> |

SUBMITTED BY

Complete (if applicable)

| | | | |
|-----------------------|---|-------------------------|------------|
| Typed or Printed Name | Joseph A. Coppola | Reg. Number | 38,413 |
| Signature |  | Date | 04/12/2002 |
| | | Deposit Account User ID | |

Application Number: 10/031,691
Filing Date: 01/22/2002
First Named Inventor: Uebele, et al.
Group Art Unit: _____
Examiner Name: _____
Attorney Docket Number: 20499P



FIRST CLASS MAIL CERTIFICATE

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE APPEARING BELOW.

MERCK & CO., INC.

MAILED BY

Karen York

DATE

April 12, 2002

20499P

APR 18 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PC1
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

| | | |
|----------------------------|-----------------------|-----------------|
| U.S. APPLICATION NUMBER NO | FIRST NAMED APPLICANT | ATTY. DOCKET NO |
| 10/031,691 | Victor Uebele | 20499P |

| |
|------------------------------|
| INTERNATIONAL APPLICATION NO |
|------------------------------|

PCT/US00/19585

| | |
|----------------|---------------|
| LA FILING DATE | PRIORITY DATE |
|----------------|---------------|


07/18/2000

Merck & Company
Patent Department, RY60-30
P O Box 2000
126 East Lincoln Avenue
Rahway, NJ 07065-0970

*Oath & Declaration
& Sequence Requirements
Due
6/3/02*

CONFIRMATION NO. 8269

371 FORMALITIES LETTER



Date Mailed: 04/03/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

LAMONT M HUNTER

Telephone: (703) 305-3686

PART 1 - ATTORNEY/APPLICANT COPY

| U.S. APPLICATION NUMBER NO. | INTERNATIONAL APPLICATION NO. | ATTY. DOCKET NO. |
|-----------------------------|-------------------------------|------------------|
| 10/031,691 | PCT/US00/19585 | 20499P |

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|-------------|--|
| Applicants: | Uebele, et al. |
| Serial No.: | 10/031,691 - Case No.: 20499P |
| Filed: | January 22, 2002 |
| For: | NOVEL HUMAN CALCIUM SENSITIVE POTASSIUM CHANNEL |

Art Unit:

Examiner:

Assistant Commissioner for Patents
Washington, D.C. 20231

SUBMISSION OF SEQUENCE STATEMENT

Sir:

Please insert the enclosed Sequence Listing in paper and computer readable form into the above-identified application. The Sequence Listing does not contain new matter. The contents of the paper and computer readable forms of the Sequence Listing are the same.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

By Karey York **MERCK & CO., INC.** Date 4/12/02

Respectfully submitted,

By Joseph A. Coppola
Joseph A. Coppola
Reg. No. 38,413
Attorney for Applicant

MERCK & CO., INC.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-6734

Date: APRIL 12, 2002